LGI1-antibody associated epilepsy successfully treated in the outpatient setting
Author
dc.contributor.author
Uribe San Martín, Reinaldo
Author
dc.contributor.author
Ciampi Díaz, Ethel
Author
dc.contributor.author
Santibáñez, R.
Author
dc.contributor.author
Irani, S. R.
Author
dc.contributor.author
Márquez, A.
Author
dc.contributor.author
Cruz, J. P.
Author
dc.contributor.author
Soler, B.
Author
dc.contributor.author
Miranda, María Cristina
Author
dc.contributor.author
Henríquez, M.
Author
dc.contributor.author
Cárcamo, C.
Admission date
dc.date.accessioned
2020-08-13T23:38:59Z
Available date
dc.date.available
2020-08-13T23:38:59Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Journal of Neuroimmunology 345 (2020) 577268
es_ES
Identifier
dc.identifier.other
10.1016/j.neuroim.2020.577268
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/176426
Abstract
dc.description.abstract
We report six patients with anti-LGI1 associated epilepsy. Two patients presented with new-onset generalized tonic-clonic seizures, four developed faciobrachial dystonic seizures and two piloerection. All patients had significant cognitive complaints at the time of diagnosis. All patients described seizure reduction during the first week of carbamazepine, and seizure freedom was obtained at a median of 13 days (range 7-22), sustained after the initiation of immunosuppression. Median time from symptom onset to carbamazepine initiation was 164 days (range 38-206 days). We discuss the particular seizure response to sodium channel blocking anti epileptic drugs, alone or associated with immunosuppression in this antibody mediated seizures.
es_ES
Patrocinador
dc.description.sponsorship
Wellcome Trust
104079/Z/14/Z
UCB-Oxford University Alliance
BMA Research Grant-Vera Down grant (2013)
BMA Research Grant-Margaret Temple (2017)
Epilepsy Research UK
P1201
National Institute for Health Research (NIHR) Oxford Biomedical Research Centre [(BRC)]